Top-Rated Stocks NASDAQ:DNLI Denali Therapeutics - DNLI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.70 -0.97 (-2.97%) (As of 02/3/2023 09:03 PM ET) Add Compare Share Share Today's Range$31.52▼$32.8150-Day Range$26.28▼$32.6752-Week Range$20.24▼$39.43Volume517,900 shsAverage Volume627,461 shsMarket Capitalization$4.31 billionP/E RatioN/ADividend YieldN/APrice Target$51.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Denali Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.5% Upside$51.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.82Based on 10 Articles This WeekInsider TradingSelling Shares$1.30 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.75 out of 5 starsMedical Sector59th out of 1,025 stocksBiological Products, Except Diagnostic Industry11th out of 168 stocks 4.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.50, Denali Therapeutics has a forecasted upside of 62.5% from its current price of $31.70.Amount of Analyst CoverageDenali Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DNLI. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 3.2 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Denali Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,300,576.00 in company stock.Percentage Held by Insiders12.70% of the stock of Denali Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.26% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Denali Therapeutics (NASDAQ:DNLI) StockDenali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.Read More Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comDenali Therapeutics' (DNLI) Outperform Rating Reaffirmed at SVB LeerinkFebruary 1, 2023 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Coverage Initiated at SVB SecuritiesFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 30, 2023 | markets.businessinsider.comExpert Ratings for Denali TherapeuticsJanuary 29, 2023 | americanbankingnews.comMorgan Stanley Boosts Denali Therapeutics (NASDAQ:DNLI) Price Target to $65.00January 25, 2023 | finance.yahoo.comDenali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiJanuary 16, 2023 | seekingalpha.comDenali: Need Patient Data To Justify That High ValuationJanuary 2, 2023 | finance.yahoo.comWith 63% ownership, Denali Therapeutics Inc. (NASDAQ:DNLI) boasts of strong institutional backingFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 13, 2022 | finance.yahoo.comLet's Take a Technical Peek at Denali TherapeuticsDecember 6, 2022 | finance.yahoo.comWe're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn RateDecember 5, 2022 | baystreet.caDenali Slumps on Drug Candidate TestsDecember 5, 2022 | technews.tmcnet.comDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialDecember 5, 2022 | finance.yahoo.comDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialNovember 9, 2022 | finance.yahoo.comDenali Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsNovember 4, 2022 | finance.yahoo.comDenali (DNLI) Lags Q3 Earnings Estimates, Pipeline in FocusNovember 4, 2022 | finance.yahoo.comDenali Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 4, 2022 | finance.yahoo.comDenali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue EstimatesNovember 4, 2022 | finance.yahoo.comAnalysts' Revenue Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Are Surging HigherNovember 2, 2022 | finance.yahoo.comWhy Denali Therapeutics' Stock Rose 6.6% on WednesdayNovember 1, 2022 | finance.yahoo.comDenali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRNOctober 29, 2022 | seekingalpha.comDenali Therapeutics: Two Shots On Goal For Parkinson's Disease TreatmentOctober 25, 2022 | benzinga.comDenali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesOctober 25, 2022 | finance.yahoo.comDenali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOctober 19, 2022 | finance.yahoo.comDenali Therapeutics Announces Pricing of $275 Million Public Offering of Common StockOctober 18, 2022 | marketwatch.comDenali Therapeutics Shares Decline 14% on Proposed Stock OfferingOctober 10, 2022 | finance.yahoo.comInvestors in Denali Therapeutics (NASDAQ:DNLI) have made a decent return of 100% over the past three yearsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Company Calendar Last Earnings11/04/2021Today2/05/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.50 High Stock Price Forecast$82.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+62.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,580,000.00 Net Margins-273.34% Pretax Margin-273.84% Return on Equity-33.85% Return on Assets-23.08% Debt Debt-to-Equity RatioN/A Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$48.66 million Price / Sales88.47 Cash FlowN/A Price / Cash FlowN/A Book Value$7.88 per share Price / Book4.02Miscellaneous Outstanding Shares135,810,000Free Float118,566,000Market Cap$4.31 billion OptionableOptionable Beta1.37 Key ExecutivesRyan J. WattsPresident, Chief Executive Officer & DirectorAlexander O. SchuthSecretary, Chief Operating & Financial OfficerCarole HoChief Medical Officer & Head-DevelopmentDana AndersenCTO & Chief Manufacturing OfficerJoe LewcockChief Scientific OfficerKey CompetitorsCRISPR TherapeuticsNASDAQ:CRSPVir BiotechnologyNASDAQ:VIRGinkgo BioworksNYSE:DNAVaxcyteNASDAQ:PCVXAbcamNASDAQ:ABCMView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 4,119 shares on 2/2/2023Ownership: 0.020%Profund Advisors LLCBought 1,905 shares on 2/2/2023Ownership: 0.011%SG Americas Securities LLCSold 8,305 shares on 2/2/2023Ownership: 0.003%Zurcher Kantonalbank Zurich Cantonalbank Bought 810 shares on 2/1/2023Ownership: 0.009%Ironwood Investment Management LLCSold 759 shares on 1/31/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions DNLI Stock - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued twelve-month target prices for Denali Therapeutics' stock. Their DNLI share price forecasts range from $38.00 to $82.00. On average, they anticipate the company's stock price to reach $51.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2023? Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have increased by 14.0% and is now trading at $31.70. View the best growth stocks for 2023 here. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.23. The company earned $5.29 million during the quarter, compared to analyst estimates of $30.28 million. Denali Therapeutics had a negative net margin of 273.34% and a negative trailing twelve-month return on equity of 33.85%. Denali Therapeutics's revenue for the quarter was down 43.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) earnings per share. What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. What is Denali Therapeutics' stock symbol? Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI." Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.13%), New York State Common Retirement Fund (0.11%), ProShare Advisors LLC (0.02%), AIA Group Ltd (0.02%), Ironwood Investment Management LLC (0.01%) and Profund Advisors LLC (0.01%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Denali Therapeutics' stock price today? One share of DNLI stock can currently be purchased for approximately $31.70. How much money does Denali Therapeutics make? Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.31 billion and generates $48.66 million in revenue each year. The company earns $-290,580,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Denali Therapeutics have? The company employs 380 workers across the globe. How can I contact Denali Therapeutics? Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com. This page (NASDAQ:DNLI) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.